Looks like you’re on the UK site. Choose another location to see content specific to your location

Home Industry News Pfizer achieves top-line result for pneumonia treatment

Pfizer achieves top-line result for pneumonia treatment

25th February 2014

Pfizer has announced it has achieved its top-line results in a landmark study of its Prevenar 13 pneumonia vaccine.

The Community-Acquired Pneumonia Immunization Trial in Adults (CAPiTA) has involved around 85,000 patients, all of which were 65 years of age or older, making it the largest double-blind, randomised, placebo-controlled efficacy research ever conducted in adults.

According to the company, the primary objective was to demonstrate the efficacy of the treatment against a first episode of vaccine-type community-acquired pneumonia (CAP).

In addition, the CAPiTA study also met the secondary targets, which were relating to its use against non-bactermic, non-invasive CAP and a first episode of vaccine-type invasive pneumococcal disease.

Dr William Gruber, Pfizer's senior vice-president for vaccine clinical research, said: "We are pleased with the outcome of the CAPiTA study, which demonstrated that Prevenar 13 can prevent vaccine-type pneumococcal community-acquired pneumonia in adults."

The results of the trial are likely to form a key consideration as the company seeks to gain new or updated recommendations for the treatment.ADNFCR-8000103-ID-801697469-ADNFCR

We currently have 6 jobs available in Pharmacy industry, find your perfect one now.

Stay informed

Receive the latest industry news, Tips
and straight to your inbox.